1-6 of 6
Tim Welliver
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Free
Krina Patel, Binod Dhakal, Gurbakhash Kaur, Richard Maziarz, Natalie Callander, Adam Sperling, Carolina Schinke, Andrzej Jakubowiak, Noa Biran, Douglas Sborov, Cindy Varga, Larry Anderson, Abhinav Deol, Abraham Kanate, Mehmet Kocoglu, Melhem Solh, Kamalika Banerjee, Krishna Rana, Ana Kostic, Enrique Granados, Carolyn Jackson, Christopher Heery, Ciara Louise Freeman, Tim Welliver, Matthew Frigault
Journal: Blood
Blood (2025) 146 (Supplement 1): 256.
https://doi.org/10.1182/blood-2025-256
Published: 2025
Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Free
Ciara Louise Freeman, Binod Dhakal, Gurbakhash Kaur, Richard T. Maziarz, Natalie Callander, Adam S. Sperling, Carolina Schinke, Andrzej J Jakubowiak, Noa Biran, Douglas W Sborov, Cindy Varga, Abhinav Deol, Abraham S. Kanate, Mehmet Hakan Koçoğlu, Melhem M. Solh, Kamalika Banerjee, Rebecca Chan, Myrna Nahas, Ana Kostic, Enrique Granados, Carolyn Jackson, Christopher R. Heery, Tim Welliver, Krina K. Patel, Matthew Frigault
Journal: Blood
Blood (2024) 144 (Supplement 1): 1031.
https://doi.org/10.1182/blood-2024-198499
Published: 2024
Journal Articles

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Free
Michael R Bishop, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika Banerjee, Rebecca J Chan, Ana Kostic, Christopher R. Heery, Tim Welliver, David Avigan, Andrzej J Jakubowiak, Matthew Frigault
Journal: Blood
Blood (2024) 144 (Supplement 1): 4825.
https://doi.org/10.1182/blood-2024-201080
Published: 2024
Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Free
Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1891.
https://doi.org/10.1182/blood-2019-127076
Published: 2019
Journal Articles

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit from Their Treatments? Real-World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression

Free
Rohan Medhekar, PhD, Dionne Hines, MPH, PhD, Sumeet Panjabi, PhD, Tim Welliver, MD PhD, Xin Wang, PhD, Rolin L. Wade, RPh, MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 836.
https://doi.org/10.1182/blood-2018-99-113414
Published: 2018
Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

Free
Ola Landgren, MD PhD, David S Siegel, MD PhD, Daniel Auclair, PhD, Ajai Chari, MD, Michael Boedigheimer, Tim Welliver, MD PhD, Khalid Mezzi, Karim Iskander, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 799.
https://doi.org/10.1182/blood-2018-99-112289
Published: 2018